This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
by Ahan Chakraborty
Keros reshaped its finances with a Takeda deal, boosting revenue and cutting R&D ??? but does it truly reduce dilution risk as 2026 uncertainty looms?
SRPTPositive Net Change PTCTPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
KROS Rinvatercept: What to Know Before DMD Phase II Starts
by Ahan Chakraborty
KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.
SRPTPositive Net Change PTCTPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics
by Sundeep Ganoria
ANIP eyes 2026 growth via Cortrophin's gout push and steady generics launches, as Rare Disease expansion reshapes priorities and investor focus.
REGNPositive Net Change ABBVNegative Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data
by Zacks Equity Research
Kura Oncology shares jump 8% as FIT-001 data show strong tumor response and disease control with darlifarnib combination in pretreated renal cancer patients.
CPRXPositive Net Change ANIPPositive Net Change KURANegative Net Change INDVPositive Net Change
biotechs medical
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?
by Sundeep Ganoria
ANI Pharmaceuticals trades at 10x forward earnings with a $93 target, but execution in Cortrophin and ophthalmology recovery may decide if the discount closes.
REGNPositive Net Change ABBVNegative Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook
by Sundeep Ganoria
ANI Pharmaceuticals rides Cortrophin Gel's surge to anchor 2026 growth, with rising guidance and new initiatives positioning the specialty portfolio for continued momentum.
REGNPositive Net Change ABBVNegative Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q1 Results?
by Ahan Chakraborty
Novo Nordisk's Q1 performance hinges on Ozempic and Wegovy sales, but rising competition, pricing pressure and muted 2026 guidance may temper growth momentum.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth?
by Sundeep Ganoria
ABBV's oncology unit faces declining Imbruvica sales and pricing pressure, likely dragging Q1 revenues despite growth from newer cancer therapies.
AZNPositive Net Change PFENegative Net Change MRKPositive Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
by Zacks Equity Research
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.
SNYPositive Net Change BIIBPositive Net Change DNLIPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
by Zacks Equity Research
CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.
BMYNegative Net Change CYTKNegative Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals